WO2003034028A3 - Methods for identifying and using modulators of estrogen related receptor gamma - Google Patents
Methods for identifying and using modulators of estrogen related receptor gamma Download PDFInfo
- Publication number
- WO2003034028A3 WO2003034028A3 PCT/US2002/032917 US0232917W WO03034028A3 WO 2003034028 A3 WO2003034028 A3 WO 2003034028A3 US 0232917 W US0232917 W US 0232917W WO 03034028 A3 WO03034028 A3 WO 03034028A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- identifying
- modulators
- receptor gamma
- related receptor
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/362—Menopause
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002342058A AU2002342058A1 (en) | 2001-10-16 | 2002-10-16 | Methods for identifying and using modulators of estrogen related receptor gamma |
JP2003536715A JP2005509628A (en) | 2001-10-16 | 2002-10-16 | Methods of identifying and using modulators of estrogen-related receptor gamma |
EP02776223A EP1436395A4 (en) | 2001-10-16 | 2002-10-16 | Methods for identifying and using modulators of estrogen related receptor gamma |
US10/491,677 US20050074765A1 (en) | 2002-10-16 | 2002-10-16 | Methods for identifying and using modulators of estrogen related receptor gamma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32988801P | 2001-10-16 | 2001-10-16 | |
US60/329,888 | 2001-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003034028A2 WO2003034028A2 (en) | 2003-04-24 |
WO2003034028A3 true WO2003034028A3 (en) | 2004-02-19 |
Family
ID=23287445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/032917 WO2003034028A2 (en) | 2001-10-16 | 2002-10-16 | Methods for identifying and using modulators of estrogen related receptor gamma |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1436395A4 (en) |
JP (1) | JP2005509628A (en) |
AU (1) | AU2002342058A1 (en) |
WO (1) | WO2003034028A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7655756B2 (en) | 2005-05-27 | 2010-02-02 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Crystallized structure of estrogen related receptor gamma in complex with bisphenol A |
KR101631581B1 (en) * | 2010-06-11 | 2016-06-17 | 한국생명공학연구원 | FRET sensor fused nano-particles and detecting method for phytoestrogen using the same |
KR101579008B1 (en) * | 2013-09-25 | 2015-12-22 | 경북대학교 산학협력단 | ERR- A composition for preventing or treating retinopathy comprising an ERR- inhibitor and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096301A (en) * | 1986-10-10 | 2000-08-01 | Industria Farmaceutica Serono Spa | Combined interferon/antiestrogen therapy for treatment of breast cancer |
US6218128B1 (en) * | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
-
2002
- 2002-10-16 WO PCT/US2002/032917 patent/WO2003034028A2/en not_active Application Discontinuation
- 2002-10-16 JP JP2003536715A patent/JP2005509628A/en active Pending
- 2002-10-16 AU AU2002342058A patent/AU2002342058A1/en not_active Abandoned
- 2002-10-16 EP EP02776223A patent/EP1436395A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096301A (en) * | 1986-10-10 | 2000-08-01 | Industria Farmaceutica Serono Spa | Combined interferon/antiestrogen therapy for treatment of breast cancer |
US6218128B1 (en) * | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
Non-Patent Citations (3)
Title |
---|
COWARD P. ET AL.: "4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 15, 17 July 2001 (2001-07-17), pages 8880 - 8884, XP002971442 * |
ROLLEROVA E. ET AL.: "Intracellular estrogen receptors, their characterization and function", ENDOCR. REGUL., vol. 34, 2000, pages 203 - 218, XP002971443 * |
See also references of EP1436395A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1436395A2 (en) | 2004-07-14 |
JP2005509628A (en) | 2005-04-14 |
AU2002342058A1 (en) | 2003-04-28 |
EP1436395A4 (en) | 2006-12-13 |
WO2003034028A2 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002325329A1 (en) | Device for distributing substances | |
AU2003281355A1 (en) | Modulators of the glucocorticoid receptor | |
HUP0201243A3 (en) | Glucocorticoid receptor modulators, pharmaceutical compositions containing them and their use | |
AU2002330039A1 (en) | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer | |
WO2002099075A3 (en) | Prmts as modifiers of the p53 pathway and methods of use | |
AU2003253535A1 (en) | N-4-piperidinyl compounds as ccr5 modulators | |
MX339420B (en) | Compounds for the modulation of ppar gamma activity. | |
WO2002099055A3 (en) | Cips as modifiers of the p53 pathway and method of use | |
HUP0104795A3 (en) | Azabicycloalkanes as ccr5 modulators, pharmaceutical compositions comprising thereof and their use | |
IL172512A0 (en) | Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them | |
AU2002215345A1 (en) | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer | |
AU2003251970A1 (en) | Modulators of the glucocorticoid receptor and method | |
AU2003228283A1 (en) | Quinazolinone modulators of nuclear receptors | |
EP1432431A4 (en) | Methods and compositions for modulating interleukin-21 receptor activity | |
AP2003002907A0 (en) | Liquid pharmaceutical composition. | |
AU2003232888A1 (en) | Electro-optical stimulation/measurement | |
AU2003298611A1 (en) | Mixed lineage kinase modulators | |
WO2001079164A3 (en) | N-substituted dithiocarbamates for the treatment of biological disorders | |
AU2001256373A1 (en) | Syringe and method for the use thereof | |
AU2003231352A1 (en) | Biocidal formulation and methods for the preparation thereof | |
AU2001284471A1 (en) | Compositions for improving mental concentration | |
TWI319762B (en) | 1,7,8-trifluoro-2-naphthol and manufacturing methods for liquid crystal compositions containing the same | |
HK1035913A1 (en) | Liquid crystal composition. | |
EP1670894B8 (en) | Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions | |
WO2003034028A3 (en) | Methods for identifying and using modulators of estrogen related receptor gamma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10491677 Country of ref document: US |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003536715 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002776223 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002776223 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002776223 Country of ref document: EP |